Pseudotyping Incompatibility between HIV-1 and Gibbon Ape Leukemia Virus Env Is Modulated by Vpu

The Env protein from gibbon ape leukemia virus (GaLV) has been shown to be incompatible with human immunodeficiency virus type 1 (HIV-1) in the production of infectious pseudotyped particles. This incompatibility has been mapped to the C-terminal cytoplasmic tail of GaLV Env. Surprisingly, we found that the HIV-1 accessory protein Vpu modulates this incompatibility. The infectivity of HIV-1 pseudotyped with murine leukemia virus (MLV) Env was not affected by Vpu. However, the infectivity of HIV-1 pseudotyped with an MLV Env with the cytoplasmic tail from GaLV Env (MLV/GaLV Env) was restricted 50- to 100-fold by Vpu. A Vpu mutant containing a scrambled membrane-spanning domain, Vpu_RD, was still able to restrict MLV/GaLV Env, but mutation of the serine residues at positions 52 and 56 completely alleviated the restriction. Loss of infectivity appeared to be caused by reduced MLV/GaLV Env incorporation into viral particles. The mechanism of this downmodulation appears to be distinct from Vpu-mediated CD4 downmodulation because Vpu-expressing cells that failed to produce infectious HIV-1 particles nonetheless continued to display robust surface MLV/GaLV Env expression. In addition, if MLV and HIV-1 were simultaneously introduced into the same cells, only the HIV-1 particle infectivity was restricted by Vpu. Collectively, these data suggest that Vpu modulates the cellular distribution of MLV/GaLV Env, preventing its recruitment to HIV-1 budding sites.The gammaretrovirus gibbon ape leukemia virus (GaLV) has been widely used for gene therapy because of its wide host cell tropism and nonpathogenicity (1, 6, 10, 12, 13, 20). The host cell receptor for GaLV Env has been cloned and identified as a sodium-dependent phosphate transporter protein (25, 26). Like other retroviruses, GaLV encodes a single transmembrane surface glycoprotein (GaLV Env), which is cleaved into surface (SU) and transmembrane (TM) subunits (Fig. ​(Fig.1).1). The TM domain of GaLV Env contains a short 30-amino-acid C-terminal cytoplasmic tail. Although GaLV Env functions well when coupled (pseudotyped) with murine leukemia virus (MLV)-based retroviral vectors, it has been shown to be completely incompatible with HIV-1 (4, 35). When GaLV Env is expressed with HIV-1, essentially no infectious HIV-1 particles are produced (4, 35). The mechanism for this infectivity downmodulation is unknown, but the component of GaLV Env responsible for the restriction has been mapped to the cytoplasmic tail. Replacing the cytoplasmic tail of GaLV Env with the equivalent sequence from MLV Env ameliorates the restriction. Likewise, replacing the cytoplasmic tail of MLV Env with that from GaLV Env confers the restriction (4).Open in a separate windowFIG. 1.Schematic of MLV Env protein. Sequences are the C-terminal cytoplasmic tails of MLV Env, GaLV Env, and human CD4. GaLV sequences in boldface are residues that have been shown to modulate the HIV-1 incompatibility (4). Underlined sequences in CD4 are amino acids required for Vpu-mediated downmodulation (2, 15). Arrows denote the location of MLV/GaLV tail substitution. SU, surface domain; TM, transmembrane domain.Vpu is an 81-amino-acid HIV-1 accessory protein produced from the same mRNA as the HIV-1 Env gene. The N terminus of Vpu contains a membrane-spanning domain, followed by a 50-amino-acid cytoplasmic domain. Vpu is unique to HIV-1 and a few closely related SIV strains. The best-characterized roles for Vpu in the HIV-1 life cycle are modulation of host proteins CD4 and tetherin (also known as BST-2, CD317, and HM1.24) (24, 38, 39). Vpu promotes the degradation of CD4 in the endoplasmic reticulum through a proteasome-dependent mechanism (29). The cytoplasmic tail of Vpu physically interacts with the cytoplasmic tail of CD4 and recruits the human β-transducing repeat-containing protein (β-TrCP) and E3 ubiquitin ligase components to polyubiquitinate and ultimately trigger the degradation of CD4 (18). Two serine residues at positions 52 and 56 of Vpu are phosphorylated by casein kinase-2 and are required for CD4 degradation (31, 32). The membrane-spanning domain of Vpu is not specifically required for CD4 degradation. A mutant protein containing a scrambled membrane-spanning sequence, Vpu_RD, is still able to trigger the degradation of CD4 (32). The region of CD4 that is targeted by Vpu is approximately 17 to 13 amino acids from the C terminus in the cytoplasmic tail (Fig. ​(Fig.1)1) (2, 15).In addition to degrading CD4, Vpu has also long been known to result in enhanced viral release (EVR) in certain cell lines (14, 36). Recently, the type I interferon-induced host protein tetherin was identified as being responsible for this Vpu-modulated restriction (24, 38). In the absence of Vpu, tetherin causes particles to remain tethered (hence the name) to the host cell postfission. Although Vpu counteracts the function of tetherin, the exact mechanism has not been fully elucidated. However, the mechanism for tetherin antagonism appears to be distinct from that for modulating CD4. Mutation of the serines 52 and 56 of Vpu abolish CD4 degradation, but only reduce EVR activity (5, 17, 21, 32). Some EVR activity remains even when much of the Vpu cytoplasmic tail is deleted (30). In addition, many mutations in the membrane-spanning domain, such as Vpu_RD, do not affect CD4 degradation and yet completely abolish EVR activity (27, 30, 37). The critical residues in tetherin for recognition by Vpu appear to be in the membrane-spanning domain and not the cytoplasmic tail (9, 19, 28). Although β-TrCP is required for complete EVR activity, there is no consensus whether the degradation of tetherin is proteasome or lysosome mediated (5, 7, 21) or whether degradation is required at all. In some cases there can be some EVR activity in the absence of tetherin degradation (17, 22).We demonstrate here that Vpu is responsible for the incompatibility between HIV-1 and GaLV Env. Glycoproteins containing the cytoplasmic tail from GaLV Env are prevented from being incorporated into HIV-1 particles by Vpu, effectively reducing infectious particle production by 50- to 100-fold. The serines at positions 52 and 56 are required for this restriction, but the membrane-spanning domain is not. Although the mechanism for this restriction appears similar to CD4 degradation, there are apparent differences. Vpu does not prevent surface expression, and it does not prevent its incorporation into MLV particles. Therefore, the mechanism of restriction appears to involve a system that does not rely directly on global protein degradation.     

Sequence Analysis of Mus dunni Endogenous Virus Reveals a Hybrid VL30/Gibbon Ape Leukemia Virus-Like Structure and a Distinct Envelope

Mus dunni endogenous virus (MDEV) can be activated from M. dunni cells by exposing the cells to hydrocortisone or 5-iodo-2′-deoxyuridine. Interference analysis has revealed that MDEV uses a receptor for cell entry that is different from those used by other murine retroviruses. The entire genome has now been sequenced, revealing a long terminal repeat (LTR)-gag-pol-env-LTR structure typical of simple retroviruses of the murine leukemia virus genus, with no additional open reading frames between env and the 3′ LTR. The LTRs and other noncoding regions of MDEV are most closely related to those of VL30 elements, while the majority of the coding sequences are most closely related to those of gibbon ape leukemia virus. MDEV represents the first example of a naturally occurring, replication-competent virus with sequences closely related to VL30 elements. The U3 region of MDEV contains six nearly perfect 80-bp repeats and the beginning of a seventh, and the region expected to contain the packaging sequence contains approximately four imperfect 33-bp repeats. The receptor specificity domains of the envelope are unique among retroviruses and show no apparent similarity to regions of known proteins.     

A Cytoplasmic Tail Determinant in HIV-1 Vpu Mediates Targeting of Tetherin for Endosomal Degradation and Counteracts Interferon-Induced Restriction

The HIV-1 accessory protein Vpu counteracts tetherin (BST-2/CD317) by preventing its incorporation into virions, reducing its surface expression, and ultimately promoting its degradation. Here we characterize a putative trafficking motif, EXXXLV, in the second alpha helix of the subtype-B Vpu cytoplasmic tail as being required for efficient tetherin antagonism. Mutation of this motif prevents ESCRT-dependent degradation of tetherin/Vpu complexes, tetherin cell surface downregulation, but not its physical interaction with Vpu. Importantly, this motif is required for efficient cell-free virion release from CD4+ T cells, particularly after their exposure to type-1 interferon, indicating that the ability to reduce surface tetherin levels and promote its degradation is important to counteract restriction under conditions that the virus likely encounters in vivo. Vpu EXXXLV mutants accumulate with tetherin at the cell surface and in endosomal compartments, but retain the ability to bind both β-TrCP2 and HRS, indicating that this motif is required for a post-binding trafficking event that commits tetherin for ESCRT-dependent degradation and prevents its transit to the plasma membrane and viral budding zones. We further found that while Vpu function is dependent on clathrin, and the entire second alpha helix of the Vpu tail can be functionally complemented by a clathrin adaptor binding peptide derived from HIV-1 Nef, none of the canonical clathrin adaptors nor retromer are required for this process. Finally we show that residual activity of Vpu EXXXLV mutants requires an intact endocytic motif in tetherin, suggesting that physical association of Vpu with tetherin during its recycling may be sufficient to compromise tetherin activity to some degree.     

New Structural Arrangement of the Extracellular Regions of the Phosphate Transporter SLC20A1, the Receptor for Gibbon Ape Leukemia Virus

Infection of a host cell by a retrovirus requires an initial interaction with a cellular receptor. For numerous gammaretroviruses, such as the gibbon ape leukemia virus, woolly monkey virus, feline leukemia virus subgroup B, feline leukemia virus subgroup T, and 10A1 murine leukemia virus, this receptor is the human type III sodium-dependent inorganic phosphate transporter, SLC20A1, formerly known as PiT1. Understanding the critical receptor functionalities and interactions with the virus that lead to successful infection requires that we first know the surface structure of the cellular receptor. Previous molecular modeling from the protein sequence, and limited empirical data, predicted a protein with 10 transmembrane helices. Here we undertake the biochemical approach of substituted cysteine accessibility mutagenesis to resolve the topology of this receptor in live cells. We discover that there are segments of the protein that are unexpectedly exposed to the outside milieu. By using information determined by substituted cysteine accessibility mutagenesis to set constraints in HMMTOP, a hidden Markov model-based transmembrane topology prediction method, we now propose a comprehensive topological model for SLC20A1, a transmembrane protein with 12 transmembrane helices and 7 extracellular regions, that varies from previous models and should permit approaches that define both virus interaction and transport function.Nearly all of the gammaretroviral receptors identified to date are members of the major carrier facilitator class of proteins (1). The cellular role of these proteins is the transport of solutes essential for cell metabolism. SLC20A1 (PiT1), the receptor for gibbon ape leukemia virus (GALV)² and feline leukemia virus subgroup B (FeLV-B), has been identified to normally function as the sodium-dependent inorganic phosphate (Na/P_i) transporter SLC20A1 (2–4). SLC20A1 is ubiquitously expressed and plays a major role in the housekeeping process of maintaining cell P_i homeostasis in transporting monovalent H₂PO₄ forms of P_i (5). This P_i transporter is important for chondroblastic and osteoblastic mineralization and vascular calcification (5).Using Kyte Doolittle hydropathy plots, the structure of SLC20A1 (PiT1) was initially predicted to contain 10 transmembrane helices (TMHs), with both the N and C termini positioned intracellularly (6). The predicted structure of SLC20A1 (PiT1) has since been modified, based on experimental data that showed both ends of the protein are extracellular and that the protein contains an N-linked glycosylation site (7); however, the number and positions of the extracellular regions (ECRs) and transmembrane helices (TMHs) remain not experimentally validated.A closely related phosphate transporter, SLC20A2 (PiT2), functions as a receptor for the murine amphotropic leukemia virus (A-MLV) (3, 8–10). Salaun et al. (11) experimentally assessed PiT2 topology using N- and C-terminal epitope tags, glycosylation studies, and in vitro translation of C-terminally epitope-tagged truncated mutants exposed to microsomal vesicles. However, as noted by these authors, C-terminally truncated PiT2 mutants in membrane vesicles can behave differently than PiT2 in the cell membrane, and thus assignment of hydrophilic loops to one side or the other of the membrane using this experimental approach provides ambiguous results (11).High resolution structural analysis of proteins such as SLC20A1 (PiT1), which pass through the cell membrane multiple times, is impeded by difficulties in purification and crystallization. To circumvent these obstacles and to increase the understanding of structure-function relationships, multiple membrane-spanning proteins can be characterized through mutational analysis in the context of their normal lipid environment within living cells. In light of this consideration, we undertook cellular topological studies of the SLC20A1 (PiT1) protein using substituted cysteine accessibility mutagenesis (SCAM), a powerful method that has been successfully employed in establishing the topology of a large number of multiple membrane-spanning proteins because it minimally perturbs the structure and function of the target protein (12). Over 50 cysteine mutants were evaluated, allowing us to construct a model for the membrane topology of SLC20A1 (PiT1), in which the protein crosses the plasma membrane 12 times.The A-MLV binding domain for its receptor, SLC20A2 (PiT2), has been experimentally determined (13); however, a region(s) within PiT1 that binds virus has not been resolved. It has been proposed that region A PiT1 residues 550–558 function as the virus-binding site, based on the loss of receptor function when the corresponding residues of PiT2 are substituted for those of PiT1 (14), and other experimental criteria that demonstrate region A is important in facilitating virus entry (15). However, it is important to note that these experiments did not include virus binding assays. Later we determined that substitution of PiT2 residues for PiT1 region A residues in fact did not abolish virus binding for FeLV-B, even though receptor function was inactivated (7). Thus, the virus-binding site for SLC20A1 (PiT1) remains unresolved. Now that we have established an experimentally validated topology for SLC20A1 (PiT1), the extracellular residues that are required for virus binding can be identified, and the effects of SLC20A1 (PiT1) receptor-inactivating mutations can be assessed with respect to whether or not they alter the ability of the virus to bind or enter cells at a post-binding stage of infection.     

Discovery of a Novel Retrovirus Sequence in an Australian Native Rodent (Melomys burtoni): A Putative Link between Gibbon Ape Leukemia Virus and Koala Retrovirus

Gibbon ape leukaemia virus (GALV) and koala retrovirus (KoRV) share a remarkably close sequence identity despite the fact that they occur in distantly related mammals on different continents. It has previously been suggested that infection of their respective hosts may have occurred as a result of a species jump from another, as yet unidentified vertebrate host. To investigate possible sources of these retroviruses in the Australian context, DNA samples were obtained from 42 vertebrate species and screened using PCR in order to detect proviral sequences closely related to KoRV and GALV. Four proviral partial sequences totalling 2880 bases which share a strong similarity with KoRV and GALV were detected in DNA from a native Australian rodent, the grassland melomys, Melomys burtoni. We have designated this novel gammaretrovirus Melomys burtoni retrovirus (MbRV). The concatenated nucleotide sequence of MbRV shares 93% identity with the corresponding sequence from GALV-SEATO and 83% identity with KoRV. The geographic ranges of the grassland melomys and of the koala partially overlap. Thus a species jump by MbRV from melomys to koalas is conceivable. However the genus Melomys does not occur in mainland South East Asia and so it appears most likely that another as yet unidentified host was the source of GALV.     

The Y-S-L-I Tyrosine-Based Motif in the Cytoplasmic Domain of the Human T-Cell Leukemia Virus Type 1 Envelope Is Essential for Cell-to-Cell Transmission

The human T-cell leukemia virus type 1 (HTLV-1) transmembrane glycoprotein has a 24-amino-acid cytoplasmic domain whose function in the viral life cycle is poorly understood. We introduced premature-stop mutations and 18 single-amino-acid substitutions into this domain and studied their effects on cell-to-cell transmission of the virus. The results show that the cytoplasmic domain is absolutely required for cell-to-cell transmission of HTLV-1, through amino acids which cluster in a Y-S-L-I tyrosine-based motif. The transmission defect in two motif mutants did not result from a defect in glycoprotein incorporation or fusion. It appears that the Y-S-L-I tyrosine-based motif of the HTLV-1 glycoprotein cytoplasmic domain has multiple functions, including involvement in virus transmission at a postfusion step.     

Antagonism to and Intracellular Sequestration of Human Tetherin by the Human Immunodeficiency Virus Type 2 Envelope Glycoprotein

Tetherin (CD317/BST-2), an interferon-induced membrane protein, restricts the release of nascent retroviral particles from infected cell surfaces. While human immunodeficiency virus type 1 (HIV-1) encodes the accessory gene vpu to overcome the action of tetherin, the lineage of primate lentiviruses that gave rise to HIV-2 does not. It has been previously reported that the HIV-2 envelope glycoprotein has a Vpu-like function in promoting virus release. Here we demonstrate that the HIV-2 Rod envelope glycoprotein (HIV-2 Rod Env) is a tetherin antagonist. Expression of HIV-2 Rod Env, but not that of HIV-1 or the closely related simian immunodeficiency virus (SIV) SIVmac1A11, counteracts tetherin-mediated restriction of Vpu-defective HIV-1 in a cell-type-specific manner. This correlates with the ability of the HIV-2 Rod Env to mediate cell surface downregulation of tetherin. Antagonism requires an endocytic motif conserved across HIV/SIV lineages in the gp41 cytoplasmic tail, but specificity for tetherin is governed by extracellular determinants in the mature Env protein. Coimmunoprecipitation studies suggest an interaction between HIV-2 Rod Env and tetherin, but unlike studies with Vpu, we found no evidence of tetherin degradation. In the presence of HIV-2 Rod Env, tetherin localization is restricted to the trans-Golgi network, suggesting Env-mediated effects on tetherin trafficking sequester it from virus assembly sites on the plasma membrane. Finally, we recapitulated these observations in HIV-2-infected CD4⁺ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication.Various stages of the replication cycle of primate lentiviruses can be targeted by host antiviral restriction factors (reviewed in reference 49). In addition to the well-characterized antiviral effects of members of the APOBEC3 family of cytidine deaminases, particularly APOBEC3G and -3F, and species-specific variants of tripartite motif family 5α, the release of nascent retroviral particles has recently been shown to be a target for a novel restriction factor, tetherin (CD317/bone marrow stromal cell antigen 2 [BST-2]) (31, 46). Tetherin is an interferon-inducible gene that was originally shown to impart a restriction on the release of mutants of human immunodeficiency virus type 1 (HIV-1) that lack a vpu gene (31, 46). In tetherin-positive cells, mature Vpu-defective HIV-1 particles are retained on the cell surface, linked to the plasma membrane (PM) and each other via protease-sensitive tethers, and can be subsequently endocytosed and accumulate in late endosomes (30, 31). Tetherin is not HIV specific and restricts the release of virus-like particles derived from all retroviruses tested (18), as well as those of filoviruses and arenaviruses (18, 19, 39).Tetherin is a small (181-amino-acid) type II membrane protein with an unusual topology that exists mainly as a disulfide-linked dimer (34). It consists of an N-terminal cytoplasmic tail, a transmembrane anchor, an extracellular domain that includes three cysteine residues important for dimerization, a putative coiled-coil, and finally a glycophosphatidyinosityl-linked lipid anchor (22) that is essential for restriction (31). Tetherin localizes to retroviral assembly sites on the PM (18, 31), and this unusual structure is highly suggestive that tetherin restricts virion release by incorporation into the viral membrane and cross-linking virions to cells. Such a mechanism would make tetherin a powerful antiviral effector that can target an obligate part of most, if not all, enveloped virus assembly strategies. Moreover, since tetherin restriction has no specific requirement for virus protein sequences, to avoid its action, mammalian viruses have evolved to encode several distinct countermeasures that specifically inhibit tetherin''s antiviral function.The Vpu accessory protein antagonizes tetherin-mediated restriction of HIV-1 (31, 46). In the presence of Vpu, tetherin is downregulated from the cell surface (2, 46) and is targeted for degradation (10, 13, 14), although whether these processes are required for antagonism of tetherin function is unclear (27). HIV-1 Vpu displays a distinct species specificity in that it is unable to target tetherin orthologues from rhesus macaques or African green monkeys (14, 25). This differential sensitivity maps to the tetherin transmembrane domain, particularly residues that are predicted to have been under high positive selection pressure during primate evolution (14, 16, 25). This suggests that tetherin evolution may have been driven in part by viral countermeasures like Vpu. Vpu, however, is only encoded by HIV-1 and its direct simian immunodeficiency virus (SIV) lineage precursors. The majority of SIVs, including the SIVsm, the progenitor of both HIV-2 and SIVmac, do not encode a Vpu protein (21). In some of these SIVs, tetherin antagonism was recently shown to map to the nef gene (16, 51). SIV Nef proteins, however, are generally ineffective against human tetherin because they target a (G/D)DIWK motif that was deleted from the human tetherin cytoplasmic tail sometime after the divergence of humans and chimpanzees (51). This raises the question of how HIV-2 is able to overcome human tetherin, as recent data show chronically HIV-2-infected CEM T cells have reduced tetherin levels on their surface (10).Interestingly, it has long been known that the envelope glycoprotein of certain HIV-2 isolates can stimulate the release of Vpu-defective HIV-1 virions from cells we now know to be tetherin positive (5, 6, 43). HIV and SIV Envs form trimeric spikes of dimers of the surface subunit (SU-gp105 in HIV-2/SIVmac and gp120 in HIV-1) that bind CD4 and the chemokine coreceptor and gp41 (the transmembrane [TM] subunit that facilitates fusion with and entry into the target cell). Envelope precursors (gp140 or gp160) are synthesized in the endoplasmic reticulum, where they become glycosylated and are exported to the surface via the secretory pathway (8). During transit through the Golgi apparatus and possibly in endosomal compartments, the immature precursors are cleaved by furin-like proteases to form mature spikes (15, 29). Multiple endocytosis motifs in the gp41 cytoplasmic tail lead to only minor quantities of Env being exposed at the cell surface at any given time (7, 40). Recent data demonstrated that the conserved GYxxθ motif, a binding site for the clathrin adaptor protein AP-2 (3), in the membrane-proximal region of HIV-2 gp41 is required to promote Vpu-defective HIV-1 release from HeLa cells (1, 32). Based on experiments with HIV-1/HIV-2 chimeric envelopes, an additional requirement in the extracellular component was suggested (1). In this study we set out to examine the Vpu-like activity of HIV-2 envelope in light of the discovery of tetherin. We demonstrate that the HIV-2 Env is a tetherin antagonist, and we provide mechanistic insight into the basis of this antagonism.     

A Single Amino Acid Mutation in the Envelope Cytoplasmic Tail Restores the Ability of an Attenuated Simian Immunodeficiency Virus Mutant To Deplete Mucosal CD4+ T Cells

Disruption of the conserved motif GYxxØ in the simian immunodeficiency virus (SIV) SIVmac239 envelope (Env) cytoplasmic tail resulted in a virus (ΔGY) that exhibited a high plasma peak but uniquely failed to acutely deplete mucosal CD4⁺ T cells. Here, we show that ΔGY containing a flanking S727P mutation that was acquired in ΔGY-infected macaques reacquired the ability to rapidly deplete CD4⁺ T cells in lamina propria. This suggests that the GYxxØ motif and S727P each contribute to SIV''s targeting to mucosal tissues.     

Palmitoylation of the Intracytoplasmic R Peptide of the Transmembrane Envelope Protein in Moloney Murine Leukemia Virus

Previously it was reported that the 16-amino-acid (aa) C-terminal cytoplasmic tail of Moloney murine leukemia virus (MoMLV) transmembrane protein Pr15E is cleaved off during virus synthesis, yielding the mature, fusion active transmembrane protein p15E and the 16-aa peptide (R peptide or p2E). It remains to be elucidated how the R peptide impairs fusion activity of the uncleaved Pr15E. The R peptide from MoMLV was analyzed by Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunostained with antiserum against the synthetic 16-aa R peptide. The R peptide resolved with an apparent molecular mass of 7 kDa and not the 4 kDa seen with the corresponding synthetic peptide. The 7-kDa R peptide was found to be membrane bound in MoMLV-infected NIH 3T3 cells, showing that cleavage of the 7-kDa R-peptide tail must occur before or during budding of progeny virions, in which only small amounts of the 7-kDa R peptide were found. The 7-kDa R peptide was palmitoylated since it could be labeled with [(3)H]palmitic acid, which explains its membrane association, slower migration on gels, and high sensitivity in immunoblotting. The present results are in contrast to previous findings showing equimolar amounts of R peptide and p15E in virions. The discrepancy, however, can be explained by the presence of nonpalmitoylated R peptide in virions, which were poorly detected by immunoblotting. A mechanistic model is proposed. The uncleaved R peptide can, due to its lipid modification, control the conformation of the ectodomain of the transmembrane protein and thereby govern membrane fusion.     

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

To evaluate antibody specificities induced by simian immunodeficiency virus (SIV) versus human immunodeficiency virus type 1 (HIV-1) envelope antigens in nonhuman primate (NHP), we profiled binding antibody responses to linear epitopes in NHP studies with HIV-1 or SIV immunogens. We found that, overall, HIV-1 Env IgG responses were dominated by V3, with the notable exception of the responses to the vaccine strain A244 Env that were dominated by V2, whereas the anti-SIVmac239 Env responses were dominated by V2 regardless of the vaccine regimen.     

Role of the Cytoplasmic Tail Amino Acid Sequences of Newcastle Disease Virus Hemagglutinin-Neuraminidase Protein in Virion Incorporation,Cell Fusion,and Pathogenicity

To determine the role of amino acid sequences of the hemagglutinin-neuraminidase (HN) cytoplasmic tail in Newcastle disease virus (NDV) replication and pathogenicity, we generated recombinant NDVs with a deletion or point mutation in the N-terminal cytoplasmic tail. The first 2-amino-acid deletion in the cytoplasmic tail did not affect the biological characteristics of NDV. However, a 4-amino-acid deletion and the substitution of alanine for serine at position 6 affected cell fusion, pathogenicity, and colocalization of the HN and M proteins of NDV, indicating that these residues of the HN cytoplasmic tail are critical for its specific incorporation into virions.Newcastle disease virus (NDV) causes a highly contagious respiratory and neurologic disease in chickens, leading to severe economic losses in the poultry industry worldwide (1). NDV is a member of the family Paramyxoviridae and has a nonsegmented, negative-sense RNA genome consisting of six genes (3′-NP-P-M-F-HN-L-5′) (7). Infection of host cells by NDV is accomplished through the interaction of two surface glycoproteins, the fusion (F) and hemagglutinin-neuraminidase (HN) proteins. The F protein directs the membrane fusion between the viral and cellular membranes, while the HN protein mediates attachment to sialic acid, has neuraminidase activity, and plays a role in fusion promotion (4).The HN protein of NDV is a type II transmembrane glycoprotein and possesses three spatially distinct domains: the ectodomain, transmembrane domain, and cytoplasmic tail. The globular ectodomain contains the sites for receptor binding and neuraminidase activity, and the transmembrane domain anchors to viral envelopes (8). The cytoplasmic tail domain contains 26 highly conserved amino acids whose functions are not well-known. In a plasmid-based expression system, truncation (23 amino acids) of the cytoplasmic tail caused improper orientation of the HN protein in the membrane insertion (13). In other paramyxoviruses, cytoplasmic tails of the HN proteins are known to play crucial roles in virus budding and assembly (10, 12). Our unsuccessful attempt to recover a recombinant NDV (rNDV) with complete deletion of the HN cytoplasmic tail also suggested that the cytoplasmic tail is required for assembly and budding of NDV. Therefore, in this study, we determined the role of amino acid sequences of the cytoplasmic tail in the NDV replication cycle. Since essential regions of the HN cytoplasmic tail for virus replication are unknown, we consecutively deleted the first 6 nucleotides (nt), 12 nt, or 18 nt of the HN cytoplasmic tail in a full-length antigenomic cDNA of NDV intermediate virulent (mesogenic) strain Beaudette C (BC) (6), thus maintaining the “rule of six” for the NDV genome (Fig. ​(Fig.1A).1A). rNDVs were recovered using our standard protocol (6). We recovered rNDVs containing 2-amino-acid deletion and 4-amino-acid deletion of the HN cytoplasmic tail (rBC/HNΔ2 and rBC/HNΔ4, respectively), indicating that only these 4 amino acids are dispensable in generating infectious virions. Since rNDV containing 6-amino-acid deletion of the HN cytoplasmic tail could not be recovered, we wanted to know the role of amino acids at positions 5 and 6 in NDV replications. The serine residue at position 6 is a potential phosphorylation site. Therefore, to determine whether phosphorylation at this site is crucial for recovery of NDV, we additionally generated rNDVs with substitution of alanine and glutamic acid for serine (rBC/HNS6A and rBC/HNS6E, respectively) to confirm its crucial role in the recovery of rNDV.Open in a separate windowFIG. 1.Constructs of recombinant NDVs containing a deletion or point mutation in the N-terminal cytoplasmic tail of the HN protein and replication and fusion index of recovered viruses in infected cells. (A) Consecutively, 6 nt, 12 nt, or 18 nt of mRNA of the HN cytoplasmic tail in a full-length antigenomic cDNA of NDV was deleted. Deletions in the HN cytoplasmic tails are indicated by the large boldface dashes. In addition, serine at position 6 was substituted with alanine and glutamic acid was substituted by changing guanine to cytidine and adenosine, respectively. (B) In vitro replication of the mutant viruses was determined in virus-infected DF-1 cells at an MOI of 0.01. The viral titers were determined by plaque assay. (C) The fusion index was determined in virus-infected Vero cells at an MOI of 0.1. Cells were stained with hematoxylin-eosin, and the fusion index was calculated as a mean number of nuclei per cell. The assay was performed three times.In vitro replication of recovered viruses was determined by plaque assay in virus-infected DF-1 cells at a multiplicity of infection (MOI) of 0.01 (5). All mutant viruses and the parental virus, rBC, grew to similar titers, indicating that alteration of the HN cytoplasmic tails did not affect their in vitro replication (Fig. ​(Fig.1B).1B). Although the rBC/HNΔ4 mutant had grown well up to 24 h postinfection, a reduction of the viral titer was detected thereafter with rapid and extensive induction of syncytia. Therefore, we determined fusion promotion activity of the mutant viruses by quantitating syncytia in virus-infected Vero cells at an MOI of 0.1 at 30 h postinfection (8) and confirmed increased fusion promotion activity of rBC/HNΔ4 followed by rBC/HNS6A compared to that of rBC (Fig. ​(Fig.1C).1C). Similarly, enhanced fusion activity was observed in other cytoplasmic tail-truncated paramyxoviruses, such as simian virus 5 and measles virus (2, 9). It has been postulated that interaction of matrix (M) protein with the cytoplasmic tails of the glycoproteins involves in a fusion-refractory conformation at the early stage of viral maturation (2). Therefore, these altered HN cytoplasmic tails could assist NDV in gaining its cell fusion competence by modulating this fusion-refractory conformation.In general, the levels of the HN protein contents on the surfaces of virus-infected cells and in the virus particles were more affected by point mutation of serine than by truncation of the cytoplasmic tail. We analyzed surface expression of the HN protein on virus-infected DF-1 cells at an MOI of 0.1. At 24 h postinfection, the cells were labeled with a monoclonal antibody against the NDV HN protein followed by anti-Alexa Fluor 488 conjugate, fixed with 4% paraformaldehyde, and analyzed by a fluorescence-activated cell sorter (AriaII; BD Bioscience) with Flowjo program (Tree Star, Inc.) (Fig. ​(Fig.2A).2A). The percentages of cells expressing the HN proteins were 89 (rBC), 78 (rBC/HNΔ2), 71 (rBC/HNΔ4), 64 (rBC/HNS6A), and 53 (rBC/HNS6E). To analyze incorporation of the HN proteins into the viral particles, the parental and mutant viruses harvested from allantoic fluid samples were purified through a 30% sucrose cushion. The viral proteins were separated on an 8% sodium dodecyl sulfate-polyacrylamide gel (Fig. ​(Fig.2B).2B). We first examined whether the mutant viruses incorporated the same levels of other viral proteins. This assay was performed by determining the ratios of the P protein to M protein. We found that similar levels of the P and M proteins were present among the different mutant viruses (Fig. ​(Fig.2B).2B). We then measured the levels of the HN proteins incorporated into the virus particles by determining the ratios of the HN protein to M protein (Fig. ​(Fig.2C).2C). The pattern of incorporation of the HN proteins into the virus particles was similar with their cell surface expression. The HN protein contents of rBC/HNΔ2 and rBC/HNΔ4 were not significantly different from that of the parental virus (P > 0.05), indicating that truncation of the cytoplasmic tail did not impair its incorporation into the viral particles. In contrast, substitution of glutamic acid for serine decreased incorporation of the HN protein into the viral particles, indicating that serine plays an important role in both cell surface expression of the HN protein and its incorporation into the viral particles.Open in a separate windowFIG. 2.Effect of alteration of the HN cytoplasmic tail on incorporation of the HN proteins into viral particles and their surface expression in DF-1 cells. (A) Surface expression of the NDV HN protein in DF-1 cells was analyzed by a fluorescence-activated cell sorter. At 24 h postinfection, DF-1 cells infected with each virus were stained with monoclonal antibody against the HN protein followed by anti-Alexa Fluor 488 conjugate. (B) Ultracentrifuge-purified viruses from infected allantoic fluid samples were separated by electrophoresis, and the gel was then stained with Coomassie brilliant blue. (C) Ratios of HN protein to M-protein levels from the parental virus and the HN cytoplasmic tail mutant viruses were quantified.We further determined the effect of cytoplasmic tail alteration on the pathogenicity of NDV in embryonated eggs and chicks (Table ​(Table1).1). The mean death time (MDT) was determined as the mean time (h) for the minimum lethal dose of virus to kill all the embryos after inoculation of 9-day-old specific-pathogen-free (SPF) embryonated chicken eggs with virus (1). The criteria for classifying the virulence of NDV strains are as follows: virulent strains take <60 h to kill embryos, intermediate virulent strains take 60 to 90 h to kill embryos, and avirulent strains take >90 h to kill embryos. Two mutant viruses (rBC/HNΔ2 and rBC/HNS6E) showed similar values of MDT compared to rBC (59 h). In contrast, the MDTs of rBC/HNΔ4 and rBC/HNS6A were 50 h and 51 h, respectively. Increased pathogenicity of these two mutants was also confirmed by an intracerebral pathogenicity index (ICPI) test in 1-day-old SPF chicks (1). The scale of the ICPI value in evaluating the virulence of NDV strains is from 0.00 (avirulent strains) to 2.00 (highly virulent NDV strains). The rBC/HNΔ4 virus had the highest ICPI value (1.61), followed by rBC/HNS6A (ICPI value of 1.58), among the parental and mutant viruses, probably due to their enhanced fusion promotion activity. In contrast, rBC/HNS6E had the lowest ICPI value (1.41), which would be associated with decreased HN protein contents detected in the viral particles and virus-infected cells. In our previous study, decreased HN protein contents in virus particles due to complete deletion of 5′ untranslated regions of the HN gene also resulted in attenuation of the virus in chickens (14). Consistently, rBC/HNΔ2 showed biological characteristics and pathogenicity similar to those of the parental virus, suggesting that aspartic acid and arginine are indispensable for the HN cytoplasmic tail of NDV.

TABLE 1.

Pathogenicity of the HN cytoplasmic tail mutant viruses in embryonated eggs and chicks

Effect of Mutations in the Human Immunodeficiency Virus Type 1 Protease on Cleavage of the gp41 Cytoplasmic Tail

We previously reported that human immunodeficiency virus type 1 (HIV-1) develops resistance to the cholesterol-binding compound amphotericin B methyl ester (AME) by acquiring mutations (P203L and S205L) in the cytoplasmic tail of the transmembrane envelope glycoprotein gp41 that create cleavage sites for the viral protease (PR). In the present study, we observed that a PR inhibitor-resistant (PIR) HIV-1 mutant is unable to efficiently cleave the gp41 cytoplasmic tail in P203L and S205L virions, resulting in loss of AME resistance. To define the pathway to AME resistance in the context of the PIR PR, we selected for resistance with an HIV-1 isolate expressing the mutant enzyme. We identified a new gp41 mutation, R236L, that results in cleavage of the gp41 tail by the PIR PR. These results highlight the central role of gp41 cleavage as the primary mechanism of AME resistance.Cholesterol-enriched membrane microdomains, often referred to as lipid rafts (4, 18, 24), play an important role in the replication of many enveloped viruses, including human immunodeficiency virus type 1 (HIV-1) (22, 30). Lipid rafts are involved in both HIV-1 entry and egress (reviewed in references 6, 22, and 30), and the lipid bilayer of HIV-1 virions is significantly enriched in cholesterol and highly saturated lipids characteristic of lipid rafts (3, 5, 8). We recently demonstrated that the cholesterol-binding polyene fungal antibiotic amphotericin B methyl ester (AME) potently inhibits HIV-1 replication. The antiviral activity of AME is due to a profound inhibition of viral entry (27, 28) and impairment of virus particle production (29).In our previous studies, we showed that the propagation of HIV-1 in the presence of AME leads to viral escape from this compound. The mutations that confer resistance map to the cytoplasmic tail (CT) of the gp41 transmembrane envelope (Env) glycoprotein (27, 28). AME-resistant mutants (P203L and S205L) overcome the defect in viral entry imposed by AME by a novel mechanism of resistance whereby the gp41 CT is cleaved by the viral protease (PR) after incorporation of Env into virions (28). The introduction of stop codons into the gp41-coding region that prematurely truncate the CT also renders virions AME resistant. In the present study, we evaluated the interplay between protease inhibitor resistance (PIR) mutations and AME resistance.     

Mutation of the TYTLE Motif in the Cytoplasmic Tail of the Sendai Virus Fusion Protein Deeply Affects Viral Assembly and Particle Production

Enveloped viruses contain glycoproteins protruding from the viral membrane. These proteins play a crucial role in the extra-cellular steps of the virus life cycle, namely attachment to and entry into cells. Their role during the intracellular late phase of virus multiplication has been less appreciated, overlooked by the documented central organizer role of the matrix M protein. Sendai virus, a member of the Paramyxoviridae family, expresses two trans-membrane proteins on its surface, HN and F. In previous work, we have shown that suppression of F in the context of an infection, results in about 70% reduction of virus particle production, a reduction similar to that observed upon suppression of the matrix M protein. Moreover, a TYTLE motif present in F cytoplasmic tail has been proposed essential for virus particle production. In the present work, using original alternate conditional siRNA suppression systems, we generated a double F gene recombinant Sendai virus expressing wt-F and a nonviable mutated TYTLE/5A F protein (F_5A). Suppression of the wild type F gene expression in cells infected with this virus allowed the analysis of F_5A properties in the context of the infection. Coupling confocal imaging analysis to biochemical characterization, we found that F_5A i) was not expressed at the cell surface but restricted to the endoplasmic reticulum, ii) was still capable of interaction with M and iii) had profound effect on M and HN cellular distribution. On the basis of these data, we propose a model for SeV particle formation based on an M/F complex that would serve as nucleation site for virus particle assembly at the cell surface.     

Identification of a Domain within the Human T-Cell Leukemia Virus Type 2 Envelope Required for Syncytium Induction and Replication

In vitro infection by human T-cell leukemia virus type 1 and 2 (HTLV-1 and HTLV-2) can result in syncytium formation, facilitating viral entry. Using cell lines that were susceptible to HTLV-2-mediated syncytium formation but were nonfusogenic with HTLV-1, we constructed chimeric envelopes between HTLV-1 and -2 and assayed for the ability to induce syncytia in BJAB cells and HeLa cells. We have identified a fusion domain composed of the first 64 amino acids at the amino terminus of the HTLV-2 transmembrane protein, p21, the retention of which was required for syncytium induction. Construction of replication-competent HTLV genomic clones allowed us to correlate the ability of HTLV-2 to induce syncytia with the ability to replicate in BJAB cells. Differences in the ability to induce syncytia were not due to differences in the levels of total or cell membrane-associated envelope or in the formation of multimers. Therefore, we have localized a fusion domain within the amino terminus of the transmembrane protein of HTLV-2 envelope that is necessary for syncytium induction and viral replication.Human T-cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) are type C retroviruses that have been associated with a variety of human malignancies. HTLV-1 is the etiological agent of adult T-cell leukemia as well as a degenerative neurological disorder, HTLV-1-associated myelopathy/tropical spastic paraparesis (28, 40, 58, 60, 83). Recent reports have also implicated HTLV-1 infection with arthropathy (42, 65), polymyosis (23, 37), and uveitis (48, 49, 51). HTLV-2 has been associated with a rare form of atypical hairy cell leukemia (62, 63, 68) as well as some cases of neuropathy (33, 39). It is estimated that between 10 million and 20 million individuals worldwide are infected with HTLV, with an overall risk of 5% of disease progression in infected individuals (14). HTLV is endemic in southern Japan, the Caribbean Basin, and Central and South America. In the United States, recent reports have identified a high proportion of HTLV, especially HTLV-2, infection in intravenous-drug abusers (44, 61, 64).Cell-to-cell contact is considered critical for the in vivo and in vitro transmission of HTLV-1 and HTLV-2, as infection by cell-free HTLV virus is inefficient in vitro and in vivo. By analogy with other enveloped viruses, HTLV infection of susceptible cells is likely mediated by the envelope glycoprotein. Antibodies against HTLV envelope are protective against infection in vivo (71, 80), and multiple epitopes that elicit neutralizing antibodies have been identified throughout the protein (31, 34, 56). Initially synthesized as a precursor protein, gp61, HTLV envelope is subsequently modified by glycosylation and cleaved into two subunits, gp46 and p21. The external surface glycoprotein, gp46, is anchored to the cell surface by noncovalent association with the transmembrane envelope glycoprotein, p21. Interaction of envelope with the as yet unidentified cellular receptor leads to cell-to-cell fusion and can result in syncytium formation.We were interested in identifying the molecular determinants of HTLV involved in syncytium formation and viral entry. Our laboratory has several cell lines that are permissive to HTLV-2- but not HTLV-1-mediated cell fusion. Therefore, we constructed recombinants between the HTLV-1 and -2 envelope genes and assayed for the loss of syncytium induction in BJAB cells and HeLa cells. Loss of a 64-amino-acid (aa) domain located at the amino terminus of the HTLV-2 transmembrane protein, p21, correlated with a loss in the ability of the envelope chimera to induce cell fusion. When the chimeric envelopes were expressed in the context of replication-competent genomic clones, there was a good correlation between syncytium induction and the ability to replicate in permissive cells. Present within the identified fusion domain is a hydrophobic region and a heptad repeat resembling a leucine zipper. We examined the contribution of the fusion domain to the structural integrity of the HTLV-2 envelope by using a vaccinia virus expression system. None of the recombinants affected the synthesis, transport, or oligomer formation of the HTLV glycoprotein complex.